Mullins P A, Shapiro L M, Aravot D A, Scott J P, Large S R, Wallwork J, Schofield P M
Cardiac Unit, Papworth Hospital, Cambridge, U.K.
Eur Heart J. 1991 Nov;12(11):1205-7. doi: 10.1093/eurheartj/12.11.1205.
We evaluated the role of percutaneous transluminal coronary angioplasty (PTCA) in a series of orthotopic cardiac transplant recipients with severe epicardial coronary occlusive disease. Ten orthotopic cardiac transplant patients treated by PTCA up to March 1990 were reviewed. All had significant epicardial coronary artery lesions (greater than 70% stenosis compared with the adjacent healthy artery) and exercise electrocardiogram or isotope perfusion evidence of myocardial ischaemia in the relevant region. Primary angiographic PTCA success was achieved in 12 of the 16 lesions attempted (75%). Mean stenosis improvement was from 80% of adjacent healthy artery (range 70-90%) to 12% (range 0-20%). Median angiographic follow-up of 9 months (2-25 months) is available for all patients. The mean recurrence rate is 33% (4 of 12 successfully treated lesions) defined as greater than 50% reduction in the original gain at the PTCA. We have shown that PTCA is technically possible in a series of cardiac transplant recipients. The primary success and recurrence rates are comparable to the use of PTCA in conventional atherosclerotic coronary disease.
我们评估了经皮腔内冠状动脉成形术（PTCA）在一系列患有严重心外膜冠状动脉闭塞性疾病的原位心脏移植受者中的作用。回顾了截至1990年3月接受PTCA治疗的10例原位心脏移植患者。所有患者均有明显的心外膜冠状动脉病变（与相邻健康动脉相比狭窄超过70%），且相关区域有运动心电图或同位素灌注心肌缺血证据。在尝试的16处病变中，12处（75%）实现了初次血管造影PTCA成功。狭窄改善平均值从相邻健康动脉的80%（范围70%-90%）降至12%（范围0%-20%）。所有患者的血管造影中位随访时间为9个月（2-25个月）。平均复发率为33%（12处成功治疗病变中的4处），定义为PTCA时原始改善程度降低超过50%。我们已经表明，在一系列心脏移植受者中，PTCA在技术上是可行的。其初次成功率和复发率与在传统动脉粥样硬化性冠状动脉疾病中使用PTCA相当。
